US Physical Therapy (USPH) 17th Annual Midwest IDEAS Conference summary
Event summary combining transcript, slides, and related documents.
17th Annual Midwest IDEAS Conference summary
26 Aug, 2026Business model and growth strategy
Operates nearly 800 locations in 45 states, primarily through about 120 local partnerships with equity interests retained by partners.
Growth driven by 25-30 organic openings and 30-70 annual acquisitions, typically at single-digit EBITDA multiples.
Partners receive monthly cash distributions and have guaranteed exit options based on updated EBITDA multiples.
Maintains local brands post-acquisition to ensure stability and minimize disruption.
Centralizes non-clinical operations, freeing partners to focus on growth and patient care.
Competitive landscape and differentiation
Competes in a fragmented market dominated by small, independent clinics and some large PE-backed entities.
Offers superior support, better payer contracts, and regular cash flow compared to highly leveraged competitors.
Provides technology, resources, and commercial contracting expertise to acquired practices.
Acquisitions are structured to retain staff and leverage existing local systems, with gradual integration of core platforms.
Financial performance and capital allocation
Revenue mix is diversified: about one-third Medicare, majority commercial, and ~10% workers’ compensation.
Average net reimbursement per visit is just under $110, with sequential growth in visits per clinic per day over 14 of the last 16 quarters.
Maintains a strong balance sheet with $220 million in debt against expected EBITDA north of $100 million.
Pays a quarterly dividend since 2012 and completed a $25 million share repurchase in Q1 at $62–$63 per share.
Latest events from US Physical Therapy
- Q2 2026 revenue up 8.5% year-over-year; net income fell, but EBITDA guidance reaffirmed.USPH
Q2 2026 - Strong organic and acquisition-driven growth, with Medicare rate tailwinds and expanding high-margin segments.USPH
The 15th Annual East Coast IDEAS Conference - Q1 2026 revenue up 7.9% to $198.3M; EBITDA guidance reaffirmed; net income declined.USPH
Q1 2026 - Proxy seeks approval for directors, executive pay, auditor, and highlights governance and ESG.USPH
Proxy filing - Record 2025 growth and new alliances position for higher 2026 EBITDA and continued expansion.USPH
Q4 2025 - Double-digit growth and high-margin expansion in injury prevention drive strong performance.USPH
16th Annual Midwest Ideas Conference - Q3 2024 delivered record patient volumes, 12% revenue growth, and major portfolio optimization.USPH
Q3 2024 - Record patient volumes and revenue growth, but net income and margins pressured by labor costs.USPH
Q2 2024 - Record Q1 patient volume, 18.1% revenue, and 23% net income growth, fueled by acquisitions.USPH
Q1 2025